Available Until 7/15/2025
View Cart

Geriatric Specialty Recertification Literature Study: Module 1A-B (Cert #L249145)

ACPE Numbers: Various – see listing below
Content Release Date: July 17, 2024
Expiration Dates: July 15, 2025
Activity Type: Application-based
CE Credits: 10 hours (BPS and ACPE)
Activity Fee: $60 (ASHP member); $115 (non-member)

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.

Module 1A: Cardiovascular and Osteoporosis: This module focuses on 2023 guidelines for chronic coronary disease, diuretic comparison and cardiovascular events, anticoagulant use and dementia, and 2023 osteoporosis guidelines. 

Module 1B: Safety, Dementia, and Depression: This module focuses on 2023 Beers Criteria, STOPP/START criteria, glucose-lowering drugs and dementia, and treatment-resistant depression in the geriatric population. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCGP recertification approved by the BPS. 

ACPE Provider with Commendation logoThe American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

  

    

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS).

Board certified pharmacists are eligible to receive up to 10 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ASHP and ACCP are approved by BPS as providers for the recertification of BCGP.

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

Module 1A: Cardiovascular and Osteoporosis

0204-9999-24-950-H01-P

5.0

 70%

Module 1B: Safety, Dementia, and Depression

0204-9999-24-951-H01-P

5.0

 75%

Module 1A: Cardiovascular and Osteoporosis
ACPE #: 0204-9999-24-950-H01-P

This module focuses on 2023 guidelines for chronic coronary disease, diuretic comparison and cardiovascular events, anticoagulant use and dementia, and 2023 osteoporosis guidelines. 

Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. Epub 2023 Jul 20. PMID: 37471501.

  • Describe the multiorganizational guideline for the management of patients with chronic coronary disease (CCD) from the American Heart Association (AHA)/American College of Cardiology (ACC) Joint Committee on Clinical Practice Guidelines
  • Develop recommendations for the management of patients with chronic coronary disease 

Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med. 2022 Dec 29;387(26):2401-2410. doi: 10.1056/NEJMoa2212270. Epub 2022 Dec 14. PMID: 36516076.

  • Describe the study by Ishani and colleagues comparing the efficacy of chlorthalidone with hydrochlorothiazide for reducing the risk of cardiovascular disease in older adults with hypertension​
  • Develop recommendations for the use of thiazide diuretics for reducing the risk of cardiovascular disease in older adults with hypertension​ 

Ouellet GM, O'Leary JR, Leggett CG, et al. Benefits and harms of oral anticoagulants for atrial fibrillation in nursing home residents with advanced dementia. J Am Geriatr Soc. 2023;71(2): 561‐568. doi:10.1111/jgs.18108

  • ​Describe the study by Ouellet and colleagues of oral anticoagulant use for stroke prevention in nursing home residents with atrial fibrillation (AF) and advanced dementia​
  • ​Develop recommendations for the use of oral anticoagulants for stroke prevention in older adults with atrial fibrillation and advanced dementia​ 

Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023 Feb;176(2):224-238. doi: 10.7326/M22-1034. Epub 2023 Jan 3. Erratum in: Ann Intern Med. 2023 Jun;176(6):882-884. PMID: 36592456.

  • Describe the American College of Physicians (ACP) clinical guideline for pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults​
  • ​Develop recommendations for the pharmacologic treatment of adults with primary osteoporosis or low bone mass to prevent fractures​

Module 1B: Safety, Dementia, and Depression
ACPE #: 0204-9999-24-951-H01-P

This module focuses on 2023 Beers Criteria, STOPP/START criteria, glucose-lowering drugs and dementia, and treatment-resistant depression in the geriatric population. 

By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4. PMID: 37139824.

  • Describe the American Geriatrics Society (AGS) 2023 updated Beers Criteria® for potentially inappropriate medication use in older adults​
  • ​Develop pharmacotherapy recommendations for older adults based on the American Geriatrics Society 2023 updated Beers Criteria® for potentially inappropriate medication use 

O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3.  Eur Geriatr Med. 2023 Aug;14(4):625-632. doi: 10.1007/s41999-023-00777-y. Epub 2023 May 31. Erratum in: Eur Geriatr Med. 2023 Jun 16;: PMID: 37256475

  • ​Describe version 3 of the STOPP/START criteria for older adults for potentially inappropriate prescribing (PIP)
  • ​Develop recommendations for older adults based on for the use of the STOPP/START criteria for potentially inappropriate prescribing 

Tang H, Shao H, Shaaban CE, et al. Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies. J Am Geriatr Soc. 2023 Jul;71(7):2096-2106. doi: 10.1111/jgs.18306. Epub 2023 Feb 23. PMID: 36821780; PMCID: PMC10363181.

  • Describe the systematic review and meta-analysis by Tang and colleagues of newer glucose-lowering drugs (sodium-glucose cotransporter [SGLT]-2 inhibitors, glucagon-like peptide [GLP]-1 receptor agonists, and dipeptidyl peptidase [DPP]-4 inhibitors) and the risk of dementia in adults with type 2 diabetes mellitus​
  • ​Develop recommendations for the use of newer glucose-lowering drugs (sodium-glucose cotransporter [SGLT]-2 inhibitors, glucagon-like peptide [GLP]-1 receptor agonists, and dipeptidyl peptidase [DPP]-4 inhibitors) in adults with type 2 diabetes mellitus​ 

Lockery JE, Collyer TA, Woods RL, et al. Potentially inappropriate medication use is associated with increased risk of incident disability in healthy older adults. J Am Geriatr Soc. 2023 Aug;71(8):2495-2505. doi: 10.1111/jgs.18353. Epub 2023 Apr 11. PMID: 37039393.​

  • Describe the study by Lockery and colleagues of the impact of potentially inappropriate medication (PIM) use in healthy community-dwelling older adults​
  • Develop recommendations for reducing potentially inappropriate medication use in healthy community-dwelling older adults​ 

Lenze EJ, Mulsant BH, Roose SP, et al. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. N Engl J Med. 2023 Mar 23;388(12):1067-1079. doi: 10.1056/NEJMoa2204462. Epub 2023 Mar 3. PMID: 36867173.

  • Describe the Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM) study by Lenze and colleagues​
  • ​Develop recommendations for the treatment of older adults with treatment-resistant depression​

Full Faculty Bios

Cyrille K. "Cye" Cornelio, PharmD, BCCP
Assistant Professor
University of South Florida Health Taneja
College of Pharmacy
Tampa, Florida 

Erica Dominguez, PharmD, BCACP
Assistant Professor of Pharmacy Practice
Texas Tech Health Sciences Center Jerry H. Hodge
School of Pharmacy
Amarillo, Texas 

Carol Fox, PharmD, BCGP, CPh
Associate Professor and Chair
Department of Pharmacotherapeutics and Clinical Research
University of South Florida Taneja College of Pharmacy
Tampa, Florida 

Thea Moore, PharmD, BCPP
Associate Professor, Vice Chair
University of South Florida
Tampa, Florida 

Sarah Visintainer, PharmD, BCGP, BCMTMS, CSP
Senior Clinical Pharmacist
Shields Health Solutions
Stoughton, Massachusetts 

Content Matter Experts

Amie Taggart Blaszczyk, PharmD, BCGP, BCPS, FASCP
Professor and Division Head – Geriatrics
Texas Tech University Health Sciences Center School of Pharmacy
Amarillo, Texas 

Dana Carroll, PharmD, BCGP, BCPS, CDES
Clinical Professor
Auburn University Harrison School of Pharmacy
University of Alabama Family Medicine
Tuscaloosa, Alabama 

Maria Shin, PharmD, BCGP, BCPS
Clinical Pharmacy Specialist in Internal Medicine
Robley Rex Louisville Veterans Affairs Medical Center
Louisville, Kentucky 

Michelle Abalos, PharmD 

Faith Alexander, BCGP
Jessica Badichek, PharmD, BCGP
Andrea Barns, BSc(Pharm), ACPR, BCGP
Kristin Bell, PharmD, BCPS, BCGP
Richard Bolitho, BPharmM
Kelsey Burke, PharmD, BCGP
Madeline Burke, PharmD, BCGP
Anshu Chen, BSPharm, PhD, BCGP
Michael Crooks, PharmD, BCGP
Cassandra Dirks, PharmD, PCGP
Barbara Fiano, BS Pharm, BCGP
Keilana Fisher, PharmD BCGP
Chihmin Fuchs, MSCP, BCGP
Sarah Fuchs, PharmD, BCGP, BCPS
Veleka Grady, PharmD, BCGP
Samantha Griffith, PharmD, BCGP
Ariane Guthrie, PharmD, BCPS, BCGP
Amanda Harmon, PharmD, BCGP, BC-ADM, CPP
Michelle Howerton, PharmD, BCACP, BCGP
Kaitlyn Jansen, PharmD, BCGP, BCPS
Jaison Joseph, PharmD, BCGP
Christina Kaminski, PharmD, BCGP
Michelle Kloppman, BScPharm, BCGP
Jessica Langton, PharmD, BCGP, CAPM
Rebecca Lee, DipClin Pharm, BCGP
Leigh Luckett, PharmD, BCPS, BCGP
Bindu Mathews, Pharm D, BCGP
Sarah Norman, PharmD, BCPS, BCPP, BCGP
Sandra Nowak, PharmD, BCGP
Abiodun Olutayo, BCGP
Rosalyn Otting, PharmD, BCGP
Zahava Picado, PharmD, BCGP
Kelsey Rasmussen, PharmD, BCGP
Melissa Reilly, PharmD, BCGP
Nahirony Sanchez, PharmD, BCPS, BCGP
Elise Shepard, PharmD, BCGP
Sierra Simpkins-Hall, PharmD, BCGPS
usan Tadros, PharmD, BCGPS
Molly Tice, PharmD, BCGP
Kristi Tribuiani, PharmD, BGCP
Susan Walls, PharmD, BCGP
Samantha Watlington, PharmD
Courtney Wong, PharmD, BCGP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

Cyrille K. "Cye" Cornelio: The research grant received was the American College of Clinical Pharmacy Ambulatory Care PRN SEED Grant was for a research project. The grant program is intended for members who are junior investigators to "foster the development of grantsmanship and research skills.". The award was given to allow investigators to pay for biostatistics support. 

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ASHP and ACCP collaborate on geriatric activities.

.